Introduction
============

Moxifloxacin hydrochloride ophthalmic solution 0.5% is the ocular formulation/adaptation of moxifloxacin, an 8-methoxyfluoroquinolone, broad spectrum, anti-infective. It was introduced in 2003 as Vigamox^®^ (Alcon Laboratories, Inc, Fort Worth, TX, USA) for the treatment of susceptible microorganisms recovered from patients with bacterial conjunctivitis. It is used more frequently off label for treatment of keratitis and as a prophylaxis agent in cataract and refractive surgeries ([@b106-co-2-77]; [@b3-co-2-77]; [@b93-co-2-77]).

It is an isotonic, preservative free, solution with a near neutral pH of 6.8. The formula of Vigamox includes 5 mg/mL (0.5%) of moxifloxacin, boric acid, and purified water. Lack of the preservative BAK (benzalkonium chloride) makes it unique among current topical antibiotics licensed for use. Vigamox is currently available in more than 40 countries. Moxifloxacin hydrochloride ophthalmic solution 0.5%, under the trade name Vegamox^®^, was introduced into Japan in 2006, with approval for the treatment of bacterial conjunctivitis, keratitis and surgical prophylaxis.

Chemistry
=========

[Figure 1](#f1-co-2-77){ref-type="fig"} shows the basic molecule and [Figure 2](#f2-co-2-77){ref-type="fig"} the moxifloxacin molecule. [Table 1](#t1-co-2-77){ref-type="table"} shows the impact of core modifications.

Moxifloxacin
============

Moxifloxacin is a broad spectrum, 8-methoxy fluoroquinolone with improved activity against Streptococci and Staphylococci and moderate to excellent activity against clinically relevant, gram negative ocular pathogens ([@b95-co-2-77]; [@b51-co-2-77]).

Modification of the parent molecule's core 4-quinolone core, at positions 1, 5, 7, and 8 has engineered novel fluoroquinolones with enhanced antimicrobial activity, safety and tolerability ([@b51-co-2-77]). Substitutions at the N-1 nitrogen atoms are critical for the spectrum of activity and potency of the molecule. The N-1 cyclopropyl substitution in moxifloxacin confers increased activity against gram-positive and anaerobic isolates. Substitutions at the C-5 position also impact the in vitro activity against gram-positive isolates; the larger the molecule the greater the gram positive potency. Addition of a bulky C-7 (diazabicyclononyl ring) side chain and a methoxy group at the C-8 position reduces the potential for selection of resistant bacterial subpopulations and increase the binding/blocking affinity for DNA gyrase and topoisomerase IV, essential bacterial enzymes ([@b20-co-2-77]; [@b6-co-2-77]; [@b5-co-2-77]; [@b87-co-2-77]; [@b115-co-2-77]; [@b12-co-2-77]; [@b92-co-2-77])

These modifications were incorporated to meet the challenge of emerging resistance in the older fluoroquinolones among ocular and nonocular isolates ([@b9-co-2-77]; [@b16-co-2-77]; [@b30-co-2-77]; [@b2-co-2-77]; [@b117-co-2-77]; [@b66-co-2-77]; [@b43-co-2-77]; [@b63-co-2-77]; [@b65-co-2-77]; [@b104-co-2-77]).

Mechanism of action
===================

Moxifloxacin is a bactericidal, concentration dependent, anti-infective. It interferes with bacterial survival by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. DNA gyrase is encoded by the genes gyra A and gyr B, while topoisomerase IV is encoded by Par C (grl A) and pare (grl B). Inhibition of either enzyme leads to bacteria death ([@b117-co-2-77]; [@b43-co-2-77]; [@b63-co-2-77]; [@b104-co-2-77]).

All fluoroquinolones bind to DNA gyrase and topoisomerase enzymes in susceptible organisms. The affinity or strength of the attachment varies; dependent on the class of fluoroquinolone and the bacteria species. Moxifloxacin binds strongly to both DNA gyrase and topoisomerase, but demonstrates preferential binding to DNA gyrase in gram-negative pathogens and *Streptococcus pneumoniae.* There is controversy as to the preferential target in the staphylococci. Preferential of dual targeting confirmation is dependent on methods used to evaluate the targets, and wild type strains employed to generate the mutants ([@b41-co-2-77]; [@b83-co-2-77]; [@b7-co-2-77]; [@b51-co-2-77]).

Studies confirmed that for the older fluoroquinolones such as ciprofloxacin, topoisomerase IV is the preferred target in gram positive bacteria ([@b6-co-2-77]; [@b18-co-2-77]; [@b24-co-2-77]; [@b116-co-2-77]). In vitro studies supporting the dual activity of moxifloxacin have been mixed. Takei and colleagues using MIC ratios; classified moxifloxacin as a class three quinolone exhibiting dual activity against the two enzymes in *Staphylococcus aureus* ([@b103-co-2-77]). Topoisomerase IV was identified as the preferential target, with purified *S. aureus* DNA gyrase and topoisomerase IV enzymes by Ince and colleagues ([@b44-co-2-77]). Griggs and co-workers ([@b31-co-2-77]) selected mutants with preferred affinity for DNA gyrase.

Exposure to fluoroquinolones may select single step mutants and or bacterial populations with increased tolerance or resistance. Mechanisms of resistance to the fluoroquinolones include subpopulations (mutants) with 1) mutations in DNA gyrase and or topoisomerase genes that alter/reduce the binding affinity of the enzymes, 2) gene mutations that block drug entry, 3) presence of an efflux pump that reduces drug accumulation and 4) unique genes that confer specific resistance against *S. aureus* ([@b115-co-2-77]; [@b113-co-2-77]; [@b63-co-2-77]; [@b45-co-2-77]; [@b104-co-2-77]). Rare or emerging resistant mechanisms include 1) the presence of plasmids that protect cells from the lethal effects of the fluoroquinolones and 2) acquisition of a fluoroquinolone modifying enzyme ([@b90-co-2-77]; [@b91-co-2-77]).

Low level fluoroquinolone resistant populations usually contain a single mutation in DNA gyrase or topoisomerase IV. The preferred or primary target varies with the bacteria species and the fluoroquinolone. Key mutations usually occur in a unique region known as the quinolone resistant determining region (QRDR) of either DNA gyrase or topoisomerase IV. Secondary mutations may also occur in genes outside of these regions, in genes encoding efflux pumps, membrane permeability and cell transport. High level resistant isolates contain multiple gene mutations both in primary and in secondary targets. In areas with preexisting low levels of fluroquinolone resistance, exposure to suboptimal levels of the new fluoroquinolones will lead to rapid progression to double mutants and high level resistance ([@b42-co-2-77]; [@b95-co-2-77]; [@b115-co-2-77]; [@b43-co-2-77]; [@b74-co-2-77]).

[Figure 3](#f3-co-2-77){ref-type="fig"} highlights the evolution of fluoroquinolones resistance among ocular isolates recovered from postoperative endophthalmitis cases from one region ([@b75-co-2-77]). At base line (1990--1994), low level resistance to ciprofloxacin (10.3%) was evident, with no documented resistance to levofloxacin, gatifloxacin, or moxifloxacin. Emergence of multistep mutants or subpopulations resistant to levofloxacin and the 8 methoxy fluoroquinolones were steeper and almost 3 times higher compared to ciprofloxacin during the initialfive years following ciprofloxacin's introduction. Increasing resistance to ciprofloxacin and levofloxacin doubled in the last 5 years. Resistant populations increased by 8.9% for gatifloxacin and 5.1% for moxifloxacin during that same time period.

Spectrum of activity
====================

In vitro studies comparing minimal inhibitory concentrations (MICs) from the United States, Asia and Europe have documented the in vitro efficacy of moxifloxacin against a broad array of ocular and nonocular pathogens ([@b9-co-2-77]; [@b60-co-2-77]; [@b115-co-2-77]; [@b12-co-2-77]; [@b18-co-2-77]; [@b43-co-2-77]; [@b51-co-2-77]; [@b63-co-2-77]). Emerging trends indicate enhanced activity and excellent coverage for *S. pneumoniae*, *Haemophilus influenzae*, and methicillin sus-ceptibile staphylococci compared to older fluoroquinolones. There was near equivocal coverage for Enterobacteriaceae, *Pseudomonas aeruginosa*, and other nonfermenters, but suboptimal coverage for methicillin resistant staphylococci and enterococci, [Table 2](#t2-co-2-77){ref-type="table"}.

Greater than 10% resistance for moxifloxacin and or gatifloxacin was documented for several ocular pathogens, including *S. pneumoniae* (11.9%), methicillin resistant *S. aureus* (95% USA, 23.3% Taiwan, methicillin resistant *Staphylococcus epidermidis* (69% USA, 40% Taiwan) and *P. aeruginosa* (18.3% Taiwan).

Currently, there are few large, credible studies evaluating in vitro activity of moxifloxacin against new and older fluoroquinolones for common ocular pathogens. Many are hampered by low numbers of isolates (less than 30 per species), incomplete panel of challenge, comparative antibiotics or spectrum of pathogens and use conflicting or outdated interpretation standards.

[Table 3](#t3-co-2-77){ref-type="table"} compares minimal inhibitory concentrations needed to inhibit 90% of pathogens (MIC~90~s) for select ocular pathogens from North and South America for ciprofloxacin, gatifloxacin, and moxifloxacin. Results are impacted by methodology, isolate mix, testing period and interpretation standard applied. Minimal inhibitory concentrations against relevant ocular pathogens indicated that the 8-methoxy fluoroquinolones have improved efficacy against common ocular pathogens compared to ciprofloxacin. MIC~90~s were 2--4 times lower for moxifloxacin versus ciprofloxacin and lower than or equivocal to gatifloxacin among important ocular pathogens. Percent susceptible ranged from 24% (methicillin-resistant staphylococci) to 100% (*S. pneumoniae*) ([@b66-co-2-77]; [@b58-co-2-77]; [@b59-co-2-77]; [@b102-co-2-77]; [@b84-co-2-77]). Isolates resistant to ciprofloxacin were in general also resistant to moxifloxacin and gatifloxacin.

Resistance patterns to the fluoroquinolones vary by region, country, and ocular site. Studies comparing endemic background ciprofloxacin resistance demonstrated wide variation across regions in Europe, and North and South America ([Table 4](#t4-co-2-77){ref-type="table"}). Emerging resistant rates to moxifloxacin and gatifloxacin correlated with background ciprofloxacin resistant rates. Regions with the highest endemic resistance also reported the highest resistant rates to moxifloxacin and gatifloxacin ([@b66-co-2-77]; [@b58-co-2-77]; [@b59-co-2-77]; [@b84-co-2-77]) ([@b75-co-2-77], unpublished).

Other microbial pathogens considered susceptible to moxifloxacin include *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Legionella pneumoniae* and the some Mycobacteria species ([@b106-co-2-77]).

Treatment of nontuberculosis with the 8-methoxyfluoroquinolones has been mixed. In a review of the early literature, Abshire and colleagues (Alcon Laboratories) offered data to support the use of moxifloxacin in the prevention and treatment on mycobacterial keratitis ([@b1-co-2-77]). Several case and series report successful treatment outcomes with the 8 methoxyfluoroquinolones as adjunctive therapy ([@b61-co-2-77]; [@b15-co-2-77] p 272; [@b46-co-2-77] p 461). Others have reported therapeutic failures with these drugs ([@b40-co-2-77]; [@b78-co-2-77]).

The majority of the mycobacterial keratitis cases have been reported following outbreaks ([@b27-co-2-77]; [@b48-co-2-77]; [@b112-co-2-77]; [@b46-co-2-77]). Increased awareness, control measures and modified surgical techniques have reduced the frequencies of mycobacterial infections in the United States. The current recommendation for treatment of mycobacterial keratitis is alternative treatment with amikacin and one of the 8-methoxyfluoroquinolones ([@b23-co-2-77]).

Case reports and series from other ocular sites have been rare ([@b32-co-2-77]; [@b109-co-2-77]; [@b81-co-2-77]; [@b100-co-2-77]; [@b68-co-2-77]). Treatment strategies include amikacin and clarithromycin ([@b109-co-2-77]).

The antifungal activities of the 8-methoxyfluoroquinolones have been investigated. There is both in vitro and in vivo evidence for some efficacy of the 8 methoyl fluoroquinolones to reduce fungal loads in the lab and for patients with contact lens associated fungal keratitis. Additional studies need to be done ([@b86-co-2-77]; [@b80-co-2-77])

Pharmacokinetics
================

Direct application of topical antimicrobial to conjunctival and corneal tissues can initially provide very high local and aqueous chamber concentrations. Final or sustained concentrations are altered by rapid tear film dissipation, underlying tissue health and dosing frequency ([@b89-co-2-77]; [@b102-co-2-77]).

Penetration of moxifoxacin has been studied in ocular tissues and fluids in both humans and animals. Human studies have revealed wide variation in drug concentrations. Recorded concentrations are impacted by route of administration, dosing frequency, site of infection, presence or absence of epithelial defect and underlying disease. The recommended dosing frequency for the treatment of bacterial conjunctivitis is one drop 3 times a day for 5 days. ([@b106-co-2-77]; [@b3-co-2-77]; [@b89-co-2-77]; [@b102-co-2-77])

In general, moxifloxacin's high concentration formulation, enhanced bioavailability, and solubility have allowed for levels 2- to 4-fold higher ocular tissues levels than gatifloxacin (Zymar^®^, Allergan, Irvine CA), ciprofloxacin (Ciloxacin^®^, Alcon, Ft. Worth, TX), levofloxacin (Quixin^®^, Vistakon Pharmaceuticals, USA), or ofloxacin (Ocuflox^®^, Allergan, Irvine, CA) ([@b13-co-2-77]; [@b14-co-2-77]; [@b29-co-2-77]; [@b95-co-2-77]; [@b22-co-2-77]; [@b43-co-2-77]; [@b63-co-2-77]; [@b55-co-2-77]; [@b89-co-2-77]; [@b15-co-2-77]; [@b82-co-2-77])

[Table 5](#t5-co-2-77){ref-type="table"} summarizes studies evaluating the penetration of moxifloxacin, gatifloxacin and ciprofloxacin into the aqueous and vitreous chambers by topical and oral routes of administration. Topical dosing protocols that mimic pre and post dosing frequencies for cataract and refractive surgeries of 4 times a day, pulsing dosing or a combination of the two, report concentration levels in the aqueous chamber that ranged from 0.38 ± 0.32 μg/mL to 2.28 ± 1.23 μg/mL.

Resultant concentration in the vitreous ranged from 0.011 ± 0.008 μg/mL to 0.11 ± 0.05 μg/mL. Vitreal concentrations were 20- to 40-fold lower than those obtained in the aqueous. ([@b22-co-2-77]; [@b35-co-2-77]; [@b36-co-2-77]; [@b49-co-2-77]; [@b52-co-2-77]; [@b53-co-2-77]; [@b99-co-2-77]; [@b17-co-2-77]; [@b70-co-2-77]; [@b85-co-2-77]). Concentration levels in the aqueous and the vitreous were usually 2-fold higher for moxifloxacin compared to gatifoxacin or ciloxacin.

Oral administration of 400--800 mg of moxifloxacin ranged from 0.21 ± 0.21 μg/mL to 2.33 μg/mL ± 0.85 and produced concentrations that were comparable to topical administration in the aqueous chamber. Drug levels were negligible in the vitreous ([@b29-co-2-77]; [@b47-co-2-77]; [@b36-co-2-77]; [@b105-co-2-77]; [@b28-co-2-77]; [@b108-co-2-77]).

Pharmacodynamics
================

The therapeutic success or potency of an antibacterial agent is a complex interrelationship between drug and its ability to reach the target site (pharmacokinetics), the microbial pathogen and susceptibility to the selective drug (pharmacodynamics), and the underlying immune status of the patient ([Figure 4](#f4-co-2-77){ref-type="fig"}).

Pharmacokinetics is the dispersion and metabolism of the drug in the body. It is defined by the absorption, distribution, dosage and protein binding characteristics of the drug, which may vary among individual drugs in a class. Pharmacodynamics defines the impact of the antimicrobial agent on the infecting microorganism. It is characterized by the bacterial species, mechanism of microbial resistance, growth phase, infecting inoculum, degree of kill, time kill and MIC distribution. The third partner in this complex relationship is what both the drug and the pathogen do to the patient. This interplay is described by the patient's age, genetic background, underlying disease and prior antimicrobial exposure.

The ratio of peak concentration (C~max~) to the MIC and the area under the concentration curve (AUC) are the pharmacodynamic indices that correlate most favorable with clinical outcomes for concentration-dependent anti-infectives. Maintaining adequate concentration of an antibiotic above a certain level known as the mutant prevention concentration (MPC) can also reduce the probability of selecting resistant subpopulations and increasing a favorable clinical outcome.

Antibiotic penetration into ocular tissues and fluids must not only reach but exceed the minimal inhibitory concentration (MIC) sufficiently to meet the targeted pharmacodynamic indices (C~max~: MIC or MPC) by a factor of 10. A C~max~:MIC ratio or MPC values greater than 10 have been documented to eradicate pathogens and suppress emergence of resistance in patients treated with fluoroquinolones ([@b4-co-2-77]; [@b73-co-2-77]; [@b96-co-2-77]; [@b39-co-2-77]).

Wilhelmus ([@b109-co-2-77]; [@b109-co-2-77]) confirmed the application and utility of pharmacodynamic indices to predict clinical outcome in patients with bacterial keratitis. The pharmacodynamic indices (PDI): C~max~:MIC and AUC:MIC were use to correlate clinical outcome for 391 patients with bacterial keratitis. Clinical improvement was associated with a C~max~:MIC ratio greater than 8 and an AUC:MIC ratio greater than 152. Corneal pathogens included *S. aureus* (21%), *P. aeruginosa* (12%), *S. pneumoniae* (7%), *Streptococcus viridans* (5%), other gram-positive isolates (44%), and other gram-negative isolates (11%).

[Table 6](#t6-co-2-77){ref-type="table"} displays calculated pharmacodynamic indices (PDI) for moxifloxacin and gatifloxacin using reported aqueous concentrations and MIC~50~s/MIC~90~s values for coagulase negative staphylococci recovered from endophthalmitis ([@b66-co-2-77]; [@b75-co-2-77])

Targeted PDIs ranged from less than or equal to 0.038 μg/mL to 0.228 μg/mL for moxifloxacin and less than or equal to 0.048--0.094 μg/mL for gatifloxacin. Obtainable moxifloxacin concentrations exceeded the MIC and met the PDI factor of 10 for 89% (8/9) and 78% (7/9) of the isolates when using the MIC~50~. None of the moxifloxacin concentrations were sufficient to provide coverage for fluoroquinolone resistant coagulase negative staphylococci for reported MIC~90~s.

Gatifloxacin concentrations met the PDI factor of 10 for 28% (2/7) of the isolates at the MIC~50~ value of 0.09 μg/mL. None of the obtainable Zymar concentrations met the PDI factor of 10 for fluoroquinolone resistant isolates at values reported by [@b75-co-2-77].

In a more recent report from the same Institution, Harper and colleagues ([@b38-co-2-77]) confirmed the low peak concentration:mic ratios for both gatifloxacin and moxifloxacin using reported intraocular levels against 59 coagulase negative staphylococci isolates collected between 1993 and 2006. Moxifloxacin ratios (C~max~:MIC~90~) were higher than gatifloxacin (0.05 μg/mL vs 0.02 μg/mL) but lower than vancomycin (0.45 μg/mL) for reported mean (1.66 μg/mL) aqueous concentrations. A significant difference in the PDI parameter was observed for moxifloxacin when the MIC~50~ rather than the MIC~90~ was used. The ratio for moxifloxacin using the MIC~50~ was 2.2 μg/mL vs 0.83 μg/mL for gatifloxacin and 0.67 μg/mL for vancomycin.

Clinical efficacy
=================

No clinical trials have been conducted evaluating moxifloxacin vs. nonfluroquinolone antibiotics for the treatment of keratitis and or endophthalmitis. In two pre-marketing, randomized, double-masked, multi-centered, controlled clinical trials to assess, safety and efficacy of moxifloxacin for the treatment of bacterial conjunctivitis, clinical cures were documented in 66%--69% of patients by day 4. Micro-biological eradication occurred in 84%--94% of the patients. Patients were dosed 3 times a day for 4 days. Age groups ranged from 2 to 92. No adverse events were reported in this group ([@b3-co-2-77]).

Deramo and colleagues reported no significant difference in the rate of endophthalmitis using 4 times a day dosing of moxifloxacin or gatifloxacin pre- and post-operative compared to established endophthalmitis infection rates. In a retrospective, multicentered review of 20,013 patients from 9 cataract centers across 7 states, the overall rate of endophthalmitis following cataract surgery was 0.07%. The rate of postoperative endophthalmitis in the gatifloxacin-treated group (81%, 16,209) was 0.06% (9 cases) and the rate for the moxifloxacin-treated group (19%, 3804) was 0.1% (5 cases). The difference was not significant (p = 0.11, nor was this rate lower than the earlier study by Miller et al using clear corneal phacoemulsification ([@b76-co-2-77]; [@b19-co-2-77]).

Safety and biocompatibility
===========================

Reported adverse reactions with 0.5% moxifloxacin hydrochloride ophthalmic solution administration have included: conjunctivitis, keratitis, decreased visual acuity, ocular hyperemia, dry eye, itching, subconjunctival hemorrhage, and tearing (Alcon Laboratories package insert) ([@b35-co-2-77]). Other infrequent ocular adverse events reported for the fluoroquinolones as a class include chemosis, eyelid edema, and punctuate epithelial keratitis ([@b63-co-2-77]).

In vitro and animals studies have demonstrated a concentration dependent toxicity in studies of corneal epithelial cell migration and or proliferation, key components in corneal wound healing ([@b64-co-2-77]; [@b22-co-2-77]; [@b57-co-2-77]; [@b10-co-2-77]; [@b25-co-2-77]; [@b72-co-2-77]; [@b89-co-2-77]; [@b99-co-2-77]; [@b21-co-2-77]; [@b50-co-2-77]; [@b62-co-2-77]; [@b69-co-2-77]; [@b71-co-2-77]; [@b101-co-2-77]; [@b107-co-2-77]).

Matsumoto and colleagues reported low and equivocal cell migration inhibition scores for moxifloxacin and gatifloxacin versus ciprofloxacin at low concentrations (\<0 .4 mmol/L), but greater toxicity for moxifloxacin and ciprofloxacin versus gatifloxacin at higher concentrations (≥0.64 mmol/L) ([@b69-co-2-77]).

McDermott and Wheater correlated dilutions and effects on migration, adhesion, collagen type four expression and presence of fibronectin of the two commercially available 8-methoxy fluoroquinolones (moxifloxacin and gatifloxacin) on human corneal and conjunctival epithelial cell lines ([@b71-co-2-77]). Increased toxicity was again correlated with higher drug concentrations. Gatifloxacin was reported to be less toxic than moxifloxacin at all concentrations.

Results of other in vitro studies evaluating, the toxicity of the 8-methoxyfluoroquinolones in human and animal corneal tissues have been mixed. Stern and colleagues used several animal models to compare the cellular effects of gatifloxacin and moxifloxacin on the rate and quality of corneal wound healing. In general, they reported greater corneal epithelial degradation, greater inhibition of collagen IV synthesis, and increased loss of normal structure in the basal lamina (Decemet's membrane) in moxifloxacin treated eyes ([@b101-co-2-77]).

In two studies from the University of Texas Southwestern Medical Center, investigators reported moxifloxacin to be less toxic to the corneal epithelium than all currently available ophthalmic fluoroquinolones ([@b57-co-2-77]). Confocal assessment documented maintenance of corneal epithelial integrity and tight junction organization after short term intense dosing with moxifloxacin versus gatifloxacin. Under similar conditions, moxifloxacin induced cell loss and breakdown of tight junctions ([@b62-co-2-77]).

Outcomes of human studies comparing the biocompatibility of moxifloxacin with gatifloxacin and or older fluoroquinolones were also mixed. In 14 healthy volunteers, where 0.5% moxifloxacin and 0.3% gatifloxacin drops were randomly administered to the right or left eye at 1 minute intervals for 5 minutes, higher levels of conjunctival injection, discomfort and corneal cell drop out per high power field were reported for the moxifloxacin eyes than for the gatifloxacin eyes. No significant change in pupil size or visual acuity was recorded for the two drugs ([@b50-co-2-77]).

Walter reported two cases of severe corneal toxicity after moxifloxacin therapy. Both patients were treated for persisted sterile corneal ulcers that worsened with intense topical dosing with moxifloxacin, but resolved after change in therapy to corticosteroids and gatifloxacin ([@b107-co-2-77]).

Donaldson and coworker reported no differences in visual acuity, tear breakup time or ocular surface integrity in the moxifloxacin treated vs. non treated eyes of healthy subjects dosed 4 times daily for 3 days. Authors concluded that moxifloxacin was safe during the 3 day treatment period that mimicked a prophylactic dosing regimen for patients scheduled for cataract surgery ([@b21-co-2-77]).

Durrie and Trattler compared the safety and tolerability of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for treatment and prophylaxis in patients undergoing laser-assisted in situ keratomileusis (LASIK) and laser-assisted subepithelial keratomileusis (LASEK). No differences between the two antibiotics was documented for visual acuity pupil size, SSPK, edema, haze, day and night-time glare halos, clarity of day or night vision, or dry eye symptoms up to 1 week in LASIK patients. Moxifloxacin and gatifloxacin were equivalent in terms of ease of use, speed of recovery, overall vision, and overall comfort for this group of patients. No differences in corneal healing were observed after LASEK surgery ([@b25-co-2-77]).

Burka et al evaluated the effect of the 8 methoxyfluoroquinolones on epithelial healing following photorefractive keratectomy (PRK). At one month follow up, the moxifloxacin treated eyes had smaller defects and healed faster than patients treated with gatifloxacin ([@b10-co-2-77]). No significant differences in visual outcomes were found in the six month follow up for these patients ([@b11-co-2-77]).

Solomon et al compared penetration and safety of ciprofloxacin, moxifloxacin and gatifloxacin in patients scheduled for cataract surgery. No clinical evidence of epithelial or intraocular toxicity was noted for any of the three drugs ([@b99-co-2-77]).

In general animal, in vitro, and clinical studies indicate the ocular and systemic safety and tolerability of moxifloxacin for the treatment of ocular infections in children (3 days to 17 years) and adults (up to age 93). Reported adverse events including conjunctivitis, keratitis and endophthalmitis have been low ([@b72-co-2-77]; [@b54-co-2-77]).

Emerging resistance issues
--------------------------

Greater than 94% of the isolates in the Endophthalmitis Vitrectomy Study were gram positive bacteria ([@b26-co-2-77]; [@b33-co-2-77]; [@b34-co-2-77]) . There are increasing reports of gram-positive pathogens recovered from post refractive surgery infections. One of the anticipated advantages of the new 8-methoxyfluoroquinolones was the increased activity (lower MICs) against resistant gram positive cocci. What has emerged among ocular and nonocular comparative studies is that the gap in improved coverage for resistant gram positive ocular pathogens is less than optimal ([@b58-co-2-77]; [@b67-co-2-77]; [@b75-co-2-77]; [@b79-co-2-77]; [@b84-co-2-77]).

Pong et al evaluated the in vitro efficacy of moxifloxacin against clinical isolates with varying degrees of resistance to ciprofloxacin. There was a high correlation between increasing ciprofloxacin resistant levels and resistant MICs for both ofloxacin and moxifloxacin for gram positive isolates. The comparative MICs, however, were lower for moxifloxacin than for ofloxacin. In general moxifloxacin MICs were 8- to 32-fold lower for gram-positive isolates and up to four fold lower for susceptible gram negative isolates than for the older fluoroquinolones ([@b88-co-2-77]).

The improved activity of moxifloxacin and gatifloxacin against methicillin resistant *S. aureus* (MRSA) does not translated to in vivo efficacy. No route of drug administration (oral, intravitreal, subconjunctival or topical) has provided concentrations that adequately cover the majority of MRSA with moderate or high level ciprofloxacin resistance.

Kotulus and colleagues documented clinical failure in a subset of 9 patients with MRSA infections treated with moxifloxacin or gatifloxacin. A third of the patients improved with continued treatment with the 8-methoxyfluoroquinolones; however, two thirds needed additional therapeutic intervention and only improved when switched to vancomycin and or other combination therapy. Patients who failed therapy were treated for an average of 4.5 days, while the third with favorable outcomes were treated more long term (18.1 days) ([@b56-co-2-77]). Others have also reported treatment failures for patients with MRSA. ([@b97-co-2-77]; [@b79-co-2-77]; [@b98-co-2-77]; [@b114-co-2-77]).

Coagulase-negative staphylococci remain the most frequent pathogen recovered from post cataract endophthalmitis. The consensus is that the origin of pathogens recovered from post cataract infections are seeded from the patient's conjunctiva. Small populations of organisms resistant to the 8 methoxyfluoroquinolones may be presence as part of the resident conjunctiva flora. These may have been "selected" following exposure to older fluoroquinolone. The high concentration and broad spectrum of the fluoroquinolone may disrupt normal conjunctival flora and allow for colonization of more resistant bacterial and or more nonbacterial pathogens.

Mino de Kaspar and colleagues demonstrated a low rate of resistance (2%) among coagulase negative staphylococci in their study evaluating the normal conjunctiva flora of patients scheduled for anterior segment surgery ([@b77-co-2-77]).

Miller et al documented a high level fluoroquinolone cross resistance among coagulase negative endophthalmitis isolates. Increasing resistance to ciprofloxacin was paralleled by increasing resistance to both moxifloxacin and gatifloxacin. Moxifloxacin provides coverage for 10/38, 26% and gatifloxacin 13/38, 66% for the ciprofloxacin-resistant isolates ([@b75-co-2-77]).

Role of moxifloxacin in the management of ocular bacterial infections
=====================================================================

No anti-infective provides ideal coverage for all pathogens for all infected sites. Selection of an effective anti-infective for ophthalmology is dependent on clinical efficacy, background resistance, site of infection, and toxicity.

Moxifloxacin hydrochloride ophthalmic solution 0.5% is a unique, preservative free, anti-infective which offers elevated tissue concentrations, broad spectrum of activity and a moderate to high rate of clinical success against common ocular pathogens. Declining efficacy against methicillin susceptible and resistant staphylococci and pseudomonas species is a concern. Judicious use is warranted to maintain utility and reduce selection of resistant populations.

![Basic 4-quinolone structure (adapted from [@b20-co-2-77]).](co-2-77f1){#f1-co-2-77}

![Moxifloxacin molecule](co-2-77f2){#f2-co-2-77}

![Evolution of fluoroquinolone resistance among coagulase negative staphylococci recovered from patients with post operative endophthalmitis (N = 78 isolates) (derived from [@b75-co-2-77]).](co-2-77f3){#f3-co-2-77}

![Factors affecting favorable outcomes during antimicrobial therapy.](co-2-77f4){#f4-co-2-77}

###### 

Impact of core modification and potency to the fluoroquinolones

  Substitution area   Structure/side effects relationship
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  R1                  This area is part of the enzyme-DNA binding complex-inappropriate stereochemistry inhibits activity. A cyclopyl substitution here increases topoisomerase binding.
  R2                  Area closes to the gyrase binding site: bulky side chains lowers potency
  R3--R4              These two groups interact with cleaved or damage DNA; no good substitutions/alternatives have been found
  R-5                 Substitutions here affects topoisomerase affinity, A NH~2~ or CH~3~ group adds gram-positive activity
  R-6                 Affects potency; NH~2~ or H possible, Interactions of (R6+7+8) are key
  R-7                 Interacts with DNA gyrase. Bulky side chain here impedes efflux; increases gram positive activity
  R-8                 Affects target affinity. A CH~3~ or OCH~3~ increases affinity against anaerobes

Adapted from [@b20-co-2-77], [@b87-co-2-77].

###### 

Comparative in vitro susceptibility of ciprofloxacin, gatifloxacin, and moxifloxacin against select nonocular pathogens

  Country                                      Time period                 Pathogen              N      MIC 90 μg/mL                                       Reference                                                   
  -------------------------------------------- --------------------------- --------------------- ------ -------------------------------------------------- --------------- ------------------------------------------- -----------------------------
  Canada                                       Collected prior to 1999                                                                                                                                                 
                                                                           *S. aureus*                                                                                                                                 
                                                                           MSSA                  365    0.125 (S)[a](#tfn2-co-2-77){ref-type="table-fn"}   0.25 (S)        ND[b](#tfn3-co-2-77){ref-type="table-fn"}   Blondeau et al 2000
                                                                           MRSA                  42     2 (R )                                             4 (R)           ND                                          
                                                                           *S. pneumoniae*       399    0.25 (S)                                           0.25--0.5 (S)   ND                                          
                                                                           *H. influenzae*       199    0.063 (S)                                          0.016 (S)       0.031 (S)                                   
                                                                           *P. aeruginosa*       1472   16                                                 8 (R)           4 (R )                                      
                                                                           *M. catarrhalis*      337    0.063 (S)                                          0.031 (S)       0.031 (S)                                   
                                                                           *P. mirabilis*        30     0.5                                                0.25 (S)        0.031 (S)                                   
  USA                                          1999--2001                  *S. pneumoniae*       3304   0.25 (S)                                           0.5 (S)         2                                           Jones et al 2003
                                                                           *H. influenzae*       3371   0.03 (S)                                           0.03 (S)        0.03 (S)                                    
                                                                           *M. catarrhalis*      1656   0.06 (S)                                           0.03 (S)        0.03 (S)                                    
  USA                                          April--December 1996        MSSA                  34     0.06 (S)                                                           1 (S)                                       Fass 1997
                                                                           MRSA                  20     4 (R)                                                              \>32 (R)                                    
                                                                           MSSE                  23     0.12 (S)                                                           0.5 (S)                                     
                                                                           MRSE                  29     2 (R)                                                              \>32 (R)                                    
                                                                           *S. pneumoniae*       50     0.25 (S)                                                           1                                           
                                                                           *H. influenzae*       45     0.03 (S)                                                           0.015 (S)                                   
                                                                           *P. mirabilis*        33     2                                                                  0.25 (S)                                    
                                                                           *P. aeruginosa*       26     = 32                                                               ≥32 (R)                                     
  Taiwan                                       1998--1999                  MSSA                  58     0.06 (S)                                                           0.5 (S)                                     Sheng Wang-Huei, et al 2001
                                                                           MRSA                  60     2 (R)                                                              16 (R)                                      
                                                                           MSSE                  58     0.12 (S)                                                           1 (S)                                       
                                                                           MRSE                  60     8 (R)                                                              128 (R)                                     
                                                                           *S. pneumoniae*       42     4 (R)                                                              128                                         
                                                                           *P. aeruginosa*       60     2                                                                  0.25 (S)                                    
  Europe (14), Israel (1), South America (3)   April 1997--February 1999   MSSA                  434    0.06 (S)                                           0.12 (S)        0.5 (S)                                     Milatovic et al 2000
                                                                           MRSA                  457    4 (R)                                              4 (R)           \>16 (R)                                    
                                                                           MSSE                  214    1 (I)                                              2 (R)           16 (R)                                      
                                                                           MRSE                  436    2 (R)                                              2 (R)           \>16 (R)                                    
                                                                           CoNS, other           111    8 (R)                                              8 (R)           \>16 (R)                                    
                                                                           *S. pneumoniae*       427    .25 (S)                                            .5 (S)          2                                           
                                                                           *S. viridans group*   97     0.25                                               0.5 (S)         4                                           
                                                                           *H. influenzae*       224    0.03 (S)                                           .015 (S)        0.15 (S)                                    
                                                                           *P. aeruginosa*       615    \>16                                               \>16            \>16 (R)                                    
                                                                           *P. mirabilis*        319    16                                                 4(R)            4 (R)                                       
                                                                           *S. marcescens*       211    4                                                  2 (S)           2 (I)                                       

Interpretations were in accordance with the Clinical and Laboratory Standard Institute (CLSI) Performance for Antimicrobial Susceptibility Testing; Seventeenth Informational Informational Supplement. M100-S17. S, sensitive, I, intermediate, R, resistant.

ND = not done. No CLSI standards for *S. pneumoniae* or *S. viridans* group and ciprofloxacin. No CLSI standards for gatifloxacin and moxifloxacin and *P. aeruginosa.* No CLSI standards for moxifloxacin *S. marcescens, S. viridans group*, and *P. mirabilis.*

**Abbreviations:** MIC~90~, concentration that inhibits 90% of isolates tested; MSSA, methicillin sensitive *Staphylococcus aureus*; MRSA, methicillin resistant *Staphylococcus aureus*; MSSE, methicillin sensitive *Staphylococcus epidermidis*; MRSE, methicillin resistant *Staphylococcus epidermidis*; P. aeruginosa, *Pseudomonas aeruginosa*, M. catarrhalis, *Moraxella catarrhalis*; S. pneumoniae, *Streptococcus pneumoniae*; H. influenzae; *Haemophilus influenzae*; P. mirabilis, *Proteus mirabilis*; S. aureus, *Staphylococcus aureus*; S. viridans group; *Streptococcus viridans* group; CoNS other, coagulase negative staphylococci other than *S. epidermidis*; S. marcescens, *Serratia marcescens*.

###### 

Comparative MIC~90~s for moxifloxacin, gatifloxacin, and ciprofloxacin against select ocular pathogens

                             Type   Ocular source          Number   MIC 90 μg/mL                                       Time Period   Reference                
  -------------------------- ------ ---------------------- -------- -------------------------------------------------- ------------- ----------- ------------ -----------------------------
  *S. aureus*                       Cornea                                                                                                                    
                             FQS                           25       0.047 (S)[a](#tfn5-co-2-77){ref-type="table-fn"}   0.22 (S)      0.5 (S)     1993--2003   [@b58-co-2-77]
                             FQR                           25       4 (R)                                              12 (R)        128 (R)                  
                             FQS    Conjunctiva isolates   20       0.094 (S)                                          0.125 (S)     0.5 (S)     1998--2002   [@b59-co-2-77]
                             FQR                           20       6.0 (R)                                            64 (R)        \>32 (R)                 
                             NOS    All ocular             21       0.25 (S)                                           0.125 (S)     0.25 (S)    2002--2004   [@b84-co-2-77]
                             MSSA   All ocular             53       1.5 (R)                                            1.5 (R)       32 (R)      2001--2006   [@b75-co-2-77], unpublished
                             MRSA                          39       32 (R)                                             32 (R)        32 (R)                   
  Coagulase negative                cornea                                                                                                                    
  Staphylococci              FQS                                                                                                                              
                                                           10       0.125 (S)                                          0.19 (S)      0.3/8 (S)   1993--2002   [@b58-co-2-77]
                             FQR                           10       3 (R )                                             3 (R)         64 (R)                   
                             FQS    Intraocular fluids     10       0.05 (S)                                           0.09 (S)      0.13 (S)    1993--2000   [@b66-co-2-77]
                             FQR                           10       2.5 (R)                                            2 (R)         2.0 (R)                  
  Coagulase Negative         NOS    all ocular             66       \>32 (R)                                           \>32 (R)      \>32 (R)    2001--2006   [@b75-co-2-77], unpublished
  Staphylococci, Coagulase          All ocular                                                                                                   2002--2004   [@b84-co-2-77]
  NegativeStaphylococci,                                                                                                                                      
                             FQS                           57       0.75 (I)                                           1 (I)         2 (I)                    
                             FQR                           21       3 (R)                                              2 (R)         \>32 (R)                 
  *S. pneumoniae*                   Cornea                 20       0.19 (S)                                           0.25 (S)      2 (I)       1993--2002   [@b58-co-2-77]
                                    Conjunctiva            20       0.09 (S)                                           0.19 (S)      0.75 (S)    1998--2002   [@b59-co-2-77]
                                    Intraocular fluids     10       0.09 (S)                                           0.22 (S)      0.75 (S)    1993--2000   [@b66-co-2-77]
                                    All ocular             20       0.19 (S)                                           0.19 (S)      3 (R)       2001--2006   [@b75-co-2-77], unpublished
                                    All ocular             16       0.12 (S)                                           0.19 (S)      1 (S)       2002--2004   [@b84-co-2-77]
  *P. aeruginosa*            FQS    Cornea                 25       0.75                                               0.38          0.094 (S)   1993--2002   [@b58-co-2-77]
                                    All ocular             40       \>32                                               \>32          \>32 (R)    2001--2006   [@b75-co-2-77], unpublished
                                    All ocular             23       2                                                  1             0.25 (S)    2002--2004   [@b84-co-2-77]
  *H. influenzae*                   Cornea                 10       0.19 (S0)                                          0.06 (S)      0.03 (S)    1993--2002   [@b58-co-2-77]
                                    Conjunctiva            20       0.12 (S)                                           0.25 (S)      1.0 (S)     1998--2002   Kowlaski et al 2005
                                    All ocular             21       0.5 (S)                                            0.32 (S)      0.19 (S)    2002--2004   [@b84-co-2-77]

Interpretations were in accordance with the Clinical and Laboratory Standard Institute (CLSI) Performance for Antimicrobial Susceptibility Testing; Seventeenth Informational Informational Supplement. M100-S17. S, sensitive; I, intermediate; R, resistant.

No CLSI standards for *S. pneumoniae* and ciprofloxacin. No CLSI standards for gatifloxacin and moxifloxacin and *P. aeruginosa.*

**Abbreviations:** MSSA, methicillin sensitive *Staphylococcus aureus*; MRSA, methicillin resistant *Staphylococcus aureus*; MIC~90~, concentration that inhibits 90% of isolates tested; FQS, fluoroquinolone sensitive; FQR, fluroquinolone resistant; NOS, *Staphylococcus aureus*, not otherwise specified or Coagulase negative staphylococci not otherwise specified.

###### 

Regional and geographic variation in endemic fluoroquinolone resistance (%) among ocular pathogens

  Region                Fluoroquinolone   Reference                                      
  --------------------- ----------------- ----------- ------ ----- --------------------- -----------------------------------------------------
  Europe                12.4              5.5         ND     532   July 2001--Dec 2002   Morrissey et al 2004
  France                12.4              5.6         ND                                 
  Germany               4.6               1.5         ND                                 
  Italy                 19.9              4.6         ND                                 
  Spain                 15.9              9.8         ND                                 
  Sweden                2.0               0           ND                                 
  UK                    8.3               8.3         ND                                 
  USA (Northeast)       28.3              13.7        20     350   1993--2005            [@b66-co-2-77]; Kowlaski et al 2003; [@b59-co-2-77]
  USA (South Florida)   30.1              16.7        23.3   431   2000--2006            [@b75-co-2-77] (unpublished)
  Brazil                14.2              11.9        11.9   183   2002--2004            [@b84-co-2-77]

ND=Not done.

###### 

Penetration studies of moxifloxacin and comparators into aqueous and vitreous humor

  Route of Administration   Dosing                                                           Dosage     Moxifloxacin             Gatifloxacin    Ciprofloxacin   Reference                          
  ------------------------- ---------------------------------------------------------------- ---------- ------------------------ --------------- --------------- --------------- ------------- ---- ------------------------
  Topical                   1 drop/2 hours × 3 days                                          43 drops   2.28 ± 1.23              0.11 ± 0.05     ND              ND              ND            ND   [@b35-co-2-77]
                            1 drop/6 hours × 3 days                                          22         0.88 ± 0.88              0.06 ± 0.06     ND              ND              ND            ND   [@b36-co-2-77]
                            1 drop/10 min prior to surgery                                   4 drops    1.80 ± 1.25                              0.48 ± 0.34                                        [@b52-co-2-77]
                            4×/day × 3 days plus 3 drops 1 hour prior to surgery             15 drops   1.31 ± 0.46                              0.63 ± 0.30                     0.15 ± 0.11        [@b99-co-2-77]
                            4 times/day 1 day prior and 1 drop prior to surgery              5 drops    1.86 ± 0.23                              0.94 ± 0.15                                        [@b70-co-2-77]
                            4 drops pre surgery                                              4 drops    1.55 ± 0.86                              0.74 ± 0.66                                        [@b49-co-2-77]
                            4 times a day/1 day before and 4 drops, pre surgery              4 drops    1.61 ± 0.71                              0.91 ± 0.54                                        
                            4 × 2 days pre op                                                8 drops    0.38 ± 0.32                              0.19 ± 0.23                                        [@b85-co-2-77]
                            4 × 2 days pre op plus 3 drops 2 hours prior to surgery          11 drops   2.16 ± 1.12                              0.82 ± 0.31                                        
                            4 × 3 days before surgery                                        12 drops                            0.011 ± 0.008                   0.008 ± 0.006                      [@b17-co-2-77]
  Oral                      2 tablets (400 mg) at 14 and 3 hours before surgery              800 mg                              1.55 ± 0.33                                                        Fuller et al 2006
                            2 tablets, evening prior to surgery and 3 hours before surgery   800 mg     1.34 ± 0.66              1.58 ± 0.80                                                        [@b36-co-2-77]
                            Single tablet 1--2 hours before surgery                          400 mg     0.21 ± 0.21              0.09 ± 0.09                                                        Vedantham et al 2005
                            Single tablet, 10 hours before surgery                           400 mg     2.33 ± 0.85                                                                                 [@b29-co-2-77]
                            Single dose Prior to surgery                                     400 mg     1.17 ± 0.40 (10 hours)                                                                      [@b108-co-2-77]
                            2 tablets, 12 hours apart                                        400 mg     1.23 ± 0.55 (12 hours)                                                                      Kampougeris et al 2007

###### 

Comparative MIC~50~s, MIC~90~s, and calculated pharmacodynamic indices for moxifloxacin and gatifloxacin for coagulase-negative staphylococci versus reported aqueous concentrations

  Drug           Source    C~max~        Calculated MIC/MPC target value   MIC~50~                MIC~50~            MIC~90~
  -------------- --------- ------------- --------------------------------- ---------------------- ------------------ ---------
                                                                           ([@b66-co-2-77])       ([@b75-co-2-77])   
  Moxifloxacin   Aqueous   0.38 ± 0.32   ≤0.038                            0.05 (FQS) 2.5 (FQR)   0.09               4
                           0.88 ± 0.88   ≤0.088                                                                      
                           1.31 ± 0.46   ≤0.131                                                                      
                           1.55 ± 0.86   ≤0.155                                                                      
                           1.61 ± 0.71   ≤0.161                                                                      
                           1.80 ±1.25    ≤0.180                                                                      
                           1.86 ± 0.23   ≤0.186                                                                      
                           2.16 ± 1.12   ≤0.216                                                                      
                           2.28 ± 1.23   ≤0.228                                                                      
  Gatifloxacin   Aqueous   0.19 ± 0.23   ≤0.019                            0.09 (FQS) 2.0 (FQR)   0.19               4
                           0.48 ± 0.34   ≤0.048                                                                      
                           0.63 ± 0.30   ≤0.063                                                                      
                           0.74 ± 0.66   ≤0.074                                                                      
                           0.82 ± 0.31   ≤0.082                                                                      
                           0.91 ± 0.54   ≤0.091                                                                      
                           0.94 ± 0.15   ≤0.094                                                                      

Derived from [@b66-co-2-77], [@b75-co-2-77].

**Abbreviations:** MIC~90~, concentration that inhibits 90% of isolates tested; MIC~50~, concentration that inhibits 50% of isolates tested; FQS, fluoroquinolone sensitive; FQR, fluroquinolone resistant.
